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Abstract
Many essential physiological pathways, such as cell proliferation, gene expression, and
cardiovascular health are regulated by Protein Arginine Methyltransferases (PRMTs) through
methylation of arginine residues in protein substrates. Understanding how PRMTs interact with
their substrates is pivotal to understanding the biological role of these enzymes, and fundamental
to the goal of identifying possible sites to be inhibited through drug therapy. Natural variations in
the N-terminus of the PRMTl enzymes and data collected in our lab suggest that the N-terminus
is important for activity and/or the binding of protein substrates. Preliminary data collected had
led us to hypothesize that the negatively charged residues in the N-terminus (Nt) of PRMTl play
an important role in substrate specificity and protein-substrate interactions. This paper details the
exploration of this hypothesis through the creation of DNA vectors for the E. coli expression of
mutant human PRMTl proteins in which varying negatively charged residues are mutated to
non-charged residues. These vectors were transformed into E. coli cells and expression and
purification of each mutant was partially optimized. Of the three hPRMTl mutants created, one
has been kinetically characterized and the activity of this mutant on three wild type PRMTI
substrates has been examined. The ultimate aim of this study, accompanied with ongoing studies
in the Hevel laboratory, is to form a complete picture of how PRMTl interacts with its substrates
and the role of the N-terminus of PRMT I in this process.
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Introduction:
The post-translational modification of proteins is an important mechanism by which organisms
are able to expand upon a limited genome. These alterations in protein structure contribute to
1
vital cell signaling pathways • Upon receipt of a stimulus, the cell responds with a signaling
cascade which concludes with a biological response. The appropriate post-translational
modification of a protein to moderate function and activity is a vital mechanism to regulate
normal cell signaling pathways and contribute to the overall health of an organism. While some
post-translational modifications have been extensively characterized, such as phosphorylation
and glycosylation, there is little known about the methylation of arginine residues on protein
substrates 1•
Protein Arginine Methyltransferases (PRMTs) are a family of enzymes that modify the
guanidinium group of an arginine residue by the addition of a methyl group. The modification of
proteins by methyl groups is specifically involved in many physiological pathways, including
1
RNA processing, signal transduction, transcriptional regulation, and protein trans location •
Protein Arginine Methyltransferases enzymatically transfer a methyl group to an arginine residue
of a protein substrate via the cosubstrate S-adenosyl-methionine (AdoMet), which acts as the
methyl group donor in the PRMT-catalyzed reaction. AdoMet is necessary for all PRMT
2
reactions and is a vital cofactor in most organisms .
The PRMT family consists of eleven isoforms, each of which have a conserved core but differ
3
extensively in the sequence of the N-terminal and C-terminal domain • Three different products
of methylation are possible: monomethylarginine, asymmetric dimethylarginine , and symmetric
dimethylarginine (Fig 1). Different products of methylation can have diverse physiological
effects, especially when normal physiological PRMT activity is disrupted. One striking example
of this can be seen with elevated levels of asymmetric dimethylarginine (ADMA), the
predominant product of PRMTl, which has been identified as a risk factor in cardiovascular
disease. ADMA has also been shown to be an inhibitor of Nitric Oxide Synthase (NOS), a
4
biologically relevant enzyme that is involved in the regulation of the elasticity of blood vessels .
What is most interesting, however, is that ADMA has been implicated in substantial changes in
gene expression in human cardiac endothelial cells. These changes were independent of the
5
arginine:NOS pathway, suggesting that ADMA ' s role exists beyond its role as a NOS inhibitor •
1 am interested in the PRMTI enzyme, which has been found to be the predominant protein
3
methylation enzyme in mammals •
This enzyme, which produces the
majority of endogenous ADMA
(Figure I), is the most conserved
isoform of PRMT and is known to
ADMA
be involved in histone methylation
1
and transcriptional regulation •
While many studies have been Figur e I. Schematic diagram of the posttr anslat ional addi t ion of met hyl
group s to th e guanidinium group o f an arginin e residu e via PRMTl
performed on this enzyme, it is
utilizing Ad oMet as a meth yl group don or.
still not fully understood how
1

PRMTI interacts with its substrates

6

.

NU.Neg

One of the predominant goals in the Hevel
E27A
lab is to elucidate how PRMTI interacts
A
complete
with
its
substrates 7 .
ESA
understanding of this interaction could lend
valuable
information
m
identifying
Figur e 2. Th e final prot ein produ ct of th e Ne-mut ants of
possible sites to be inhibited through drug
hPRMTI. Th e asterisks indi cate th e region of the N-terminu s
therapy. Previous studies in the Hevel lab
th at consta ins th e glutamate to alanin e mutati ons. Th e
and in the PRMT field have suggested that
Histidin e6 tag (blu e box) is beside th e T EV cleavage sequ ence
different lengths of N-termini can alter
(green box) , followed by th e PRMTl prot ein (indi cated by th e
purpl e box).
substrate specificity6. In trying to elucidate
the role of the N-terminus of PRMTl, the
specific amino acid sequence of the N-terminus was analyzed and a number of negatively
charged amino acids in the N-terminus were identified. Because substrates of PRMTI are
positively charged guanidinium groups, it could be possible that there is an interaction between
the positively charged substrate and the negatively charged residues on the N-terminus. We
hypothesize that the negatively charged amino acids of the N-terminus of hPRMTl may function
in regulating enzymatic activity and are also involved in protein-protein interactions with
substrates. We believe that the negatively charged amino acids in the N-terminus of PRMTI are
important in PRMT I activity because they interact with positively charged residues of the
protein substrate , forming a substrate orientation that is favorable for catalysis.
The purpose of this project was to determine if the negatively charged amino acids of the Nterminus play a role in forming a favorable substrate orientation for catalysis, which is important
for PRMTI activity . This hypothesis was and will continue to be tested by creating a variety of
mutants of hPRMTI in which a permutation of the negatively charged amino acids in the Nterminus are mutated to neutral charges (glutamate residues will be mutated to alanine residues).
First, I created vectors containing histidine-tagged hPRMTl mutants for protein expression (see
figure 2) . Second, I optimized expression and purification of one of the hPRMTl protein
mutants . After successful expression and purification of all of the hPRMTI mutants , I will
incubate the mutant proteins with wild type hPRMTI substrates and obtain kinetic data for each
mutant. This data will be compared to the kinetic data obtained from wild type hPRMTI to
determine if there is a significant difference in protein methylation between the constructs.
Materials and Methods:
Creation of Histidine-tagged

mutant hPRMTI genes:

A human PRMTI mutant termed Nt~NEG, in which all five of the N-terminal glutamate
residues (E5A, E 12A, E 19A, E22A, E27 A) were mutated to alanine residues, was ordered from
GenScript (a gene synthesis facility). This gene arrived in a pUC57-simple vector. The vector
was transformed into DH5a E. coli cells and the plasmid containing the Nt~NEG gene was
purified using a DNA purification kit from Qiagen. The plasmid concentration was determined
using a nanodrop spectrophotometer. Seven hundred ng of plasmid was digested using fast digest

2

enzymes Xho I and Kpn I from
Fermentas and then visualized using
B501
gagaagcccaacgctgcggacatgacatccaaa a 0.8% agarose gel, from which the
tttggatgtcatgtccgcagcgttgggcttctc
B502
successfully digested products were
gel extracted and purified using a
gaatggcggcagccgcggccgcgaactgc
B503
Qiagen
gel extraction kit. The
B504
gcagttcgcggccgcggctgccgccattc
NtL'-.NEGinsert was then ligated into
Figure 3. A tabl e showing each of the primer sequences for the creat ion
previously cut pET45b + expression
of E5A hPRMTl and E2 7A hPRMT I constructs. BS0 I and BS02 coded
vector
using T4 DNA
ligase
for th e mut at ion in E5A hPRMTI and BS03 and BS04 coded for th e
(Fermentas) in a 3:1 molar ends ratio
mutation in E27A hPRMTI.
at room temperature for 30 minutes .
Products of the ligation reaction were transformed into DH5a E. coli cells for plasmid
regeneration and expression. The resulting plasmid was extracted using the same Qiagen plasmid
purification kit and sent to the Center for Integrated Biosystem 's sequencing facilities for
confirmation of correct ligation . After sequencing data was confirmed to be correct, the NtL'-.Neg
hPRMTI mutant was transformed into BL2 I, C4 I (from Lucigen), and NiCo21 (DE3) E. coli
cells (from New England Biolabs).
Primer Name Primer Sequence

After successfu l creation of the NtL'-.NEG hPRMTI mutant , DNA encoding wild type hPRMTI
in the pET45b+ vector was used to create two more ex pression vectors encoding mutant
hPRMTI proteins. Both the E5A hPRMTI (primers BS0l and BS02) and E2 7A hPRMTl
(primers BS03 and BS04) mutants were created using the QuikChange Site Directed
Muta ge nesis Kit from Agilent following the exact protocol provided by the company . Following
PCR of the vector using the correct mutag enic primers (see figure 3), the DNA was dige sted with
DPN I fast digest enzyme to remove the original template DNA and the resulting product was
transform ed into DH5a E. coli cells. DNA plasmid was purifi ed usin g a Qiagen kit and sent to
sequen cing at the Center for Integ rated Bio syste ms (USU) for sequencing. After verification of
succ essfu l seque nc e identity, the plasmid was tran sfo rmed into BL21 DE3 E. co li cells and a
sma ll amount was grown to test the E.coli expression of each of these plasmids.
Express ion Optimization:
An E.co li colony (containing the NtL'-.NEG or other PRMTI mutan t gene within the expression
plasmid) was used to inoculate a 50 mL Luria-Bertani (LB) starter culture. This culture was
grown at 37 degrees Celsius for 12 hours and then I mL of the starter culture was used to
inoculate one 500 mL culture. This culture was grown at 37 degrees Celsius until it reached an
optical density of 0 .8, at which it was induced with 0.5 mM IPTG to express protein . After IPTG
induction , cultures were incubated for 24 hours at room temperature and subsequently harvested
usin g centrifugation at 8000 RPM . 0 .5 grams of each cell growth (NtL'-.NEG, E5A hPRMTI , and
E27A hPRMTI) were resuspended (each in separate tubes) in I mL of 50 mM phosphate , 0.1 M
NaCl , 20 mM imidazole buffer at pH 7.6 and lysed using sonication level 50% duty cycle power
level 5. Cell lysates were harvested using centrifugation at 14,000 RPM for 20 minutes and
supernatants were applied to 400 µL of packed Qiagen nickel sepharose resin. After a two hour
incubation period , unbound protein was collected via centrifugation. The nickel resin was
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wa shed five times with buffer containing 50 mM phosphate, 0.1 M NaCl, 20 mM imidazole (pH
7.6) , washed five times with buffer containing 50 mM phosphate, 0 . 1 M NaCl , 60 mM imidazole
(pl-I 7.6), and then protein was eluted from the nickel sepharose resin using buffer containing 50
mM phosphate, 0.1 M NaCl , and 250 mM imidazole (pH 7.6). Samples of each of these steps
were collected and analyzed using SOS-PAGE electrophoresis on a 12% acrylamide gel ran at
120 volts to stack and 180 volts for
Buffer Name Buffer Contents (all buffers at pH 7.6)
separation of protein bands. After staining
A
50 mM sodium phosphate
B
50 mM sodi um pho sphate , 30 mM imidazole
with Coomassie brilliant blue stain , the
C
50 mM sod ium phosphate , 60 mM imidazo le
protein with the best expression was chosen
D
50 mM sodium phosphate , 100 mM imidazo le
E
50 mM sodium phosphat e, 500 mM im idazole
to proceed
for initial
large scale
F
50 mM sod ium pho sph at e, 0.1 M NaCl, 1 mM OTT,2 mM EDTA
purification
efforts.
The
constructs
G
50 mM sodium pho sphate , 0.1 M NaCl
H
50 mM sodium pho sph ate , 0.1 M NaCl, 30 mM im idazole
encoding Nt.6.Neg and E5A hPRMTl were
I
50 mM sod ium pho sphate, 0.1 M NaCl, 50 mM imidazole
put through additional optimization of
Figure 4. A tab le showing each of the bu ffers used in the E27A
expression and purification efforts.
hPRMT I purification protocol. These buffers were used in a
n ickel batc h bin din g puri ficatio n , a TE V cleavage protoco l, as
well as an ion exchange colum n for the purpose ofE27A
hPRMTI pur ificatio n .

Purification:

After successful expression opt1m1zation,
E27A hPRMTl E. coli BL21 DE(3) cells
were grown in LB broth and induced at an OD of 0.8 with IPTG . Cells were harvested using an
ultracentrifuge at 8,000 RPM, which yielded l 6.1 grams of E27 A hPRMTl-containing
cells.
7.99 grams of these cells were resuspended in 35 mLs of Buffer A (see figure 4 for buffer
contents of all buffers) . Cells were lysed using sonication (4 rounds of 10 pulses at 50% duty
cycl e power level 5) and centrifuged at 17000 RPM for 20 minutes . Supernatant was applied to
2.5 mL s o f equilibrated Qiagen resin (split into two tubes for maximum resin packing during
ce ntrifugation) and incubated for three hour s at 4 de grees centigrade . All centrifugation steps in
the following protocol were performed at 700g for 3 minutes and each wa sh utilized IO mLs of
buffer per tube. All unbound proteins were collected and the resin was washed five times with
Buffer A. The resin was then washed five
times with buffer B and five times with
buff er C followed by five times with buffer
D. Protein was eluted from the nickel
sepharose resin using two mLs of buffer E
and the elution process was repeated five
times . Samples of each of these steps were
collected and analyzed using SOS-PAGE
z
z
~
~ ~
a.
n 0n
... t:!~
a.
... ...
'O
electr ophoresis on a 12% acrylamide gel.
'O
~
~
'O
~
"& 'O 'O~
'O
"& 'O "&
'O
-0
Fractions containing
the purest E27 A
Figur e 5. A SOS-PAGE gel of expression tests of the Net. Neg
protei n . N rt. Neg was transform ed into N iCo2 1DE(3), BL21,
hPRMTI were pooled and filtered before
and
C41 cell lines and expressed at roo m temp eratu re after
being placed in dialysis in buffer F and
induc tion by !PTG for 5 hours or 10 hour s (represen ted by a
incubated with l 00 µL of 2.0 mg/mL TEV
*) or indu ced at 0 .6 OD instead of 0 .8 (represent ed by a **) .
protease overnight. Cleaved protein was
Low levels o f expr essio n were seen in each cell type, but none
then dialyzed into buffer G before being reof th e cells overexpr essed Net. N eg in high qu ant ities.
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incubated over the same 2.5 mLs of reequilibrated Qiagen nickel sepharose resin
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and allowed to bind to the resin for three
hours. Unbound protein was collected via
centrifugation and the resin was then washed
five times with IO mLs of buffer G, washed
five times with buffer H, five times with
buffer I, and eluted five times with 2.0 mLs
of buffer E. Samples of each step were
SOS-PAGE
on
ran
and
collected
Each sample containing
electrophoresis.
Figure 6. The first att empted purifi cation of the Net.Neg
E27 A hPRMTl were pooled and filtered
protein expressed from NiCo21 (DE3) cells, the most soluble
before I :4 dilution (to dilute the 0.1 M
cell line. Ge l shows the pellet, supern atant , unb ou nd, wash 1
NaCl) with buffer A. Diluted sample was
(Wl) and last wash (LW) as well as elutions 1-4 (El-4). A red
loaded onto an equilibrated I mL mono Q
box in lanes El-E3 shows th e putative Net.N eg.
ion exchange column purchased from GE
healthcare. The column was washed with I 0
mL s of buffer A before a IO mL gradient of buffer A to buffer A+ I M NaCl was applied. The
column was then washed with buffer A+ I M NaCl for IO mLs. Fractions were collected and
analyzed using SOS-PAGE electrophoresis. Fractions containing purified E27A hPRMTI were
collected and filtered using a Millipore 0.22 µM filter. Filtered protein was placed in a 30 kDa
concentrator from Millipor e and was concentrated to 1.45 mg/mL in the pres ence of I 0%
glycero l before it was beaded and frozen at -80 degrees Celsius.
r-

"'
a.

Measurement of hPRMTl mutant activity:
Figure 7. Histid ine-tagged Nt .6.N egwes tern

To test the ability of the E27A hPRMTl
blot prob ed with anti-(HIS) 6 The N et.Neg
mutant to successfully methylate hPRMT I
prot ein was identified as the band that has
had a red box placed aro und it in figure 6.
substrate s, E27 A hPRMT I was initially
screened for activity using the R3 peptide
and the Z ipTip method previou sly described
Figure 8. Histidin e-tagged ESA
Meth y lation was
by the Hevel labs.
hPRMTI western blot exposed to
ant i-PRMTl (left) and ant-{HIS)6
incorporation
measured by radiolabeled
(S- antibo dies after nickel batch binding
SAM
tritiated
usin g
_,
purification of expressed ESA
adenosylmethionine ). T his was mea sured
hPRMTl. This western blot
usin g a di sco ntinuous assay that measures
confi rms the presen ce and slight
the amount of methylation vs. time s. This
expression of ESA hPRMTl protein.
assay was performed with the R3 peptide as
substrates
well as wild type hPRMTI
Figure 9. E27A hPRMTI before and
TEV cleavage of the Histidin e
after
hnRNPK and histone H4 at 37 degrees with
tag. The red box encompasses the
timpoints taken at 0, 1, 2, 4, and 6 minutes.
prot ein before cleavage (left), and after
100 nM E27A hPRMTl enzyme was used in
cleavage (the right two lanes). The
counting
Scintillation
this experiment.
cleaved lanes also have TEV protea se
visible (surr ound ed by the blue box).
revealed DPMs for each of the time points ,

__

.if
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which was subsequently converted to µM
methylations per minute . Activity levels
were then compared to wild type hPRMTI.
Results:
Ntt.Neg expression tests , identification ,
and pilot purification:
The Ntt.Neg gene was synthesized by
GenScript, a gene synthesis facility. After
arrival at the Hevel lab , it was successfully
t.)
.,:.. UI
a,
digested out of the pUC57 simple vector
..... 0)
w
and
inserted into a pET45b + expression
Figure 10. SOS-PAGE gel of E27 A hPRMTI muta nt after TEV
vector. The vector was then transformed
cleavage and Mono Q ion exchange purific ation. The E27A
hPRMTI protein is seen purified here in low and high
into E. coli cells. The fully recombinant
conce ntrations in lane F2 (Fraction number 2) and F3 (red box
hPRMT I Ntt.NEG
contains a hexasurrounds th e protein).
histidine tag followed by a sequence that
is c leavab le by TEV (tobacco etch virus) protease. Small amounts of E. coli cells were grown
and lyse d to determine presence and approximate concentration of the Ntt.Neg protein in the
supernatant. This result was inconclusive (see figure 5). For more conclusive results , a small
amount of E. coli cells were lysed and the supernatant from this procedure was placed over
nickel batch binding affinity chromatography . Elutions and supernatants were analyzed by SOS PAG E chromatography.

.,, .,, .,, .,, .,, .,, .,,

T his res ult was also inconclusive as several bands were purified by this procedure and it was
difficult to determine which band was the Ntt.Neg protein and which band was a contaminant
(see figure 6). To resolve this , each elution
00251
was run on another SOS-PAGE gel and
transferred to a membrane for Western Blot
Analysis using anti-PRMTI antibody (see
figure 7). After succe ss ful identification of a
PRMT product , it was determined that
,'
,'
exp ress ion optimization would have to be
00 1
undertaken before this protein product would
be able to be fully purified.
0 005

ESA
hPRMTI
purification:

expression

and

,'

pilot

The ESA hPRMT I gene was created via the
successful mutation of hPRMT I using two
mutagenesis
primers.
After
sequence
verification , the plasmid was transformed
into E. coli cells and a small growth was
performed. Three grams of E. coli cells was

Tim e

Figure 11. E27A hPRMTI activity assay with R3 peptide with
and without OTT . E27A hPRMTI was assayed at 100 nM
with the R3 peptide. Activity with OTT (dashed line) was
.00372 pM methylations/minure and without OTT (solid
line) it was .000628 1.1Mmetlwlations/minure.
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applied to nickel sepharose resin for batch
binding affinity chromatography. Elution
1.07 nM CH3/min
hnRNPK700 nM
and supernatant samples were run on SDS
hnRNPK850 nM
1.03 nM CHJmin
page to identify purity level. It was unclear
2.04 nM CHJmin
hnRNPK3000 nM
if the protein was purified in this
3.79 nM CHJmin
hnRNPK4000 nM
experiment, as there were many bands of
1.74 nM CHJmin
H4120 nM
contaminant proteins and none of the
2.27 nM CHJmin
H4 200 nM
proteins were of higher concentration in the
3.14 nM CHJmin
H42000 nM
elution samples. Samples from each of the
2.48 nM CHJmin
H4 3000 nM
steps in the batch binding process were run
Figur e 12. Methylation rates o fE27A hPRMTl mut ant with
on an SDS-PAGE gel and transferred to a
Histo ne H4 and hnRNPK. Aft er determinin g that th e assays
membrane for Western Blot analysis to be
requir ed th e utili zation of OTT , th e E27A hPRMTI mut ant
probed with anti-PRMTI and anti-(HIS) 6
was assayed with two PRMT I prote in substrates, Histo ne H4
(see figure 8). This blot allowed for the
and hnRN PK.
of the ESA
identification
successful
hPRMT I protein m SOS-PAGE analysis and helped to determine which elutions from the
original batch binding purification to pool for TEV cleavage. After determining that ESA
hPRMTI was successfully expressed, the elutions containing ESA hPRMTl were pooled
dialyzed with TEV protease. The cleaved protein was concentrated using a I mL mono Q anion
exchange chromatography purification as previously described. At the end of the purification
scheme , the ESA hPRMTl protein had visible degradation and wasn't completely clean. The
pilot expression and purification protocol has been established and the ESA hPRMT I protein
will be purified in the next few weeks.
ProteinSubstrateand
Concentration

Methylation Rate with EZ7A
hPRMTl

E27 A hPRMTl purification and kinetic characterization:
E27A hPRMTI was successfully created using the Quik-Change Site Directed Mutagenesis Kit
and its sequence has been verified. E27 A hPRMTI was expressed in BL2 I DE(3) E. coli cells
and purified using a nickel affinity batch binding technique followed by TEV protease cleavage
(see figure 9). TEV protease and uncleaved E27 A hPRMTl was removed using another nickel
sepharose affinity batch binding method. The purified E27 A hPRMTl was then buffer
exchanged and concentrated using a Qiagen 1 mL mono q ion exchange column and then a
Millipore 30 kDa concentrator. Protein was beaded and stored at -80 degrees Centigrade in I 0%
glycerol (see figure 10).
E27 A hPRMTl activity was then determined using the Zip Tip assay , which is a discontinuous
methylation incorporation assay. E27 A hPRMTI was first assayed using the R3 peptide substrate
of wild type hPRMTI both with and without the presence of OTT , a reductant. The E27 A
hPRMTI construct had fourfold higher activity in the presence of the reductant (see figure 11).
The E27 A hPRMTl protein was assayed with two different protein substrates, hi stone H4 and
hnRNPK at a concentration close to Vmax and also a concentration close to Km. Rates of each
of these were determined and compared against each other (see figure 12).
Discussion and Future Work:
7

This project has resulted in the successful creation of three hPRMTI mutants, Nt~Neg, E5A
hPRMTl, and E27A hPRMTI (see figure 2). Each of these has shown some expression in BL21
DE(3) E. coli cells. The majority of this project was spent in the optimization of the purification
protocol for E27A hPRMTl.
Following purificati<;m, E27A hPRMTI was kinetically
characterized with a variety of PRMTl substrates. When E27 A hPRMTl was assayed with R3, a
peptide substrate, in the presence of the reductant DTT, activity increased fourfold. I hypothesize
that the DTT reductant is restoring activity of previously oxidized amino acid residues. It is
possible that these residues were oxidized during the purification process of the enzyme. This is
consistent with other PRMT isoforms and a ratPRMTI construct that has been studied in our lab.
One member of the Hevel laboratory is studying this through the creation of a cysteine-less
ratPRMTl construct (which cannot be subject to oxidative damage) and will finalize the
purification and kinetic characterization of this enzyme in the coming months . This will be
investigated further as it may represent a natural signaling mechanism to control the activity of
PRMTl in vivo.
[nitial characterization studies of E27 A hPRMTl with protein substrates Histone H4 and
hnRNPK show lower activity rates than the rates of E27 A hPRMTI with the R3 peptide. Each of
the assays with protein substrates were performed in the presence of DTT. The activity rates of
E2 7 A hPRMTl with both Hi stone H4 and hnRNPK increased substantially with higher
concentrations of substrate , which is to be expected. These rates still need to be compared to wild
type activity . Currently, the only data of activity that we have in the lab is on wild type full
length hPRMTI or constructs in which portions of the N-terminus have been truncated. The
E27 A hPRMTI construct is not comparable with E27 hPRMTI (one enzyme that has been
kinetically characterized) because the E2 7 hPRMTl construct does not have the first 26 amino
acids of the N-terminus present. To determine if the mutation (E27 A) makes a difference in
substrate specificity, kinetic data of wild type hPRMTI must be obtained in the proper phosphate
buffer. This will be performed in the next few weeks and comparisons will be made between the
rates.
Before these rates can be compared, multiple zip-tip assays will be performed to provide enough
data to create full saturation curves, allowing us to determine specific kinetic parameters that
help us understand how the methylation occurs at the molecular level. These assays will be
performed on a variety of substrates and then compared with the results of the wild type
hPRMTI assays performed. In addition to performing assays on substrates , assays with
hypomethylated cell extracts will be performed. The hypomethylated cell extracts are mice
embryonic stem cells that have had PRMTI knocked-out. This knock-out eliminates all
endogenous PRMTl, ensuring that all native PRMTl substrates are not methylated. These
assays will provide a more complete picture of the hPRMTl mutant's activity .
The E27 A hPRMTl mutant expresses and purifies to a greater degree than the Nt~Neg hPRMTl
or E5A hPRMTl constructs. The E27 A hPRMTl mutant expresses at a much higher rate than
both the E5A hPRMTI construct and the Nt~Neg construct in multiple cell lines. Expression
tests of Nt~Neg and E5A hPRMTI have been performed in three difference E. coli cell types,
each with different expression properties , and no difference has been observed in expression
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level. I hypothesize that this could be because of the mutations in the N-terminus of the protein ,
which is translated first by the ribosome. The mutations at the distal area of the N-terminus may
destabilize the protein in some way. This could contribute to the reason why our previous
attempted construct, Nt28 (a construct of just the 28 amino acids of the N-terminus), was not
soluble or purifiable. There are additional E. coli cell lines that will be tried in the coming weeks
to attempt to optimize expression of these cells, such as arctic express (Agilent) and codon+
DE(3) cells (Stratagene). Additionally, if optimization cannot be performed , large scale
purification and purification optimization may be attempted without expression optimization.
The E5A hPRMT I construct is more soluble than the Nt-0.Neg hPRMT 1 construct in BL2 l
D E(3) E.coli cells. This may be because it only has one of the negatively charged residues in the
N-terminus mutated to alanine (compared to five mutations in Nt-0.Neg). Pilot full scale
purification has been completed and very small enzyme yields have been observed. Expression is
extremely low and additional concentration steps will be added between each purification step in
order to be able to see the increase in purity between each step and ensure successful cleavage by
TEV protease. The Mono Q ion exchange chromatography step will be optimized using the Jon
Excha nge Chromatography
Principles and Methods Handbook published by Amersham
Biosciences to opt imize the correct gradient protocol to effectively concentrate and purify this
enzyme as much as possible. This purification protocol will be optimized in the coming weeks
and enzy me activity will be assayed in a similar way to the activity assays performed on E27A
hPRMTI.
In addition to the Nt-0.Neg, E5A, and E27 A, further constructs may be made with additional
combinations of glutamate to alanine mutations in the N-terminus if the final results of these
three mutants do not give definitive results that help us to understand the role of the N-terminus.
These constructs will be created one mutation at a time from the current wild type and mutant
hPRMTI constructs using a QuikChange Site Directed Mutagenesis Kit. This kit will help us to
create a vector to encode a protein that expresses only one ( or a few) of the mutations that
Nt-0.NEG contains .
Conclusion:
In this paper, three hPRMT I mutants have been created. One mutant, E27 A hPRMTI has been
shown to be active on protein and peptide substrates and has been kinetically characterized. Two
mutants, E5A hPRMTI and Nt,0.Neg hPRMTI have been tested for expression and purification
but require optimization before large enough quantities of enzyme can be obtained for kinetic
characterization. Once all enzymes have been purified and kinetically characterized, their
activities will be compared to wild type hPRMTl to determine what role the negative charges in
the N-terminus have on substrate specificity.
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